References to Primarv Literature
- GLENNER G, WONG C: Biochem. Biophys. Res. Commun.(1984) 120: 885–890.
- MASTERS C et at.; Proc. Natl. Acad. Sci. USA (1985) 82:4245–4249.
- DYRICS T, WEIDEMANN A, MLTLTHAUP G et at.: EMBO J (1988) 7: 949–957.
- KANG J etal.: Nature (1987) 325: 733–736.
- SELKOE D: TINS (1993) 16: 403–409. A recent review describing the processing of PAPP
- ESH F, KEIM P, BEATTIE E et al.: Science (1990) 248: 1122–1124.
- SISODIA S: Proc. Natl. Acad. Sci. USA (1992) 89: 6075–6079.
- WEIDEMANN A et al.: Cell (1989) 57: 115–126.
- GOLDE T, ESTUS S, YOUNKIN L et aL: Science (1992) 233:728–730.
- HAASS C, KOO E, MELLON A et at.; Nature (London)(1992)357: 500–503.
- PIKE C, BURDICK D, WALENCEWICZ A et at.: J. Neurosci.(1993) 13: 1676–1687.
- SIMMONS L, MAY P, TOMASELLI K etal.: MoL PharmacoL (1994) 45: 373–379. Referencers 11 and 12 report a correlation between the aggregation state of fiA4 and neutrotoxicity in neuronal cultures.
- WASCO W et al.: Proc. Natl. Acad. WA (1992) 89: 10758–10762.
- NITSCH R, SLACK B, WURTMAN R, GROWDON J: Science(1993) 258: 304–307. First report of a muscarinic receptor-mediation of the rapid release of PAPP
- SEUI3ERT P et at.: Nature (1992) 359: 325–327.
- SHOJI M etal.: Science (1992) 258: 126–129.
- GOEDERT M, JAKES R, CROWTHER R etal.: Proc. Natl. Acad. Sci. WA (1993) 90: 5066–5070. Identifies the serine202 of adult tau as an abnormal phosphorylation site in Alzheimer's disease.
- KOWALL N, BEAL M, BUSCIGLIO J, DUFFY L, YANKNER B: Proc. Natl. Acad. Sci. USA (1991) 88:7247–7251.
- MARX J: Science (1992) 255: 1200–1202.
- BUXI3AUM J, CHRISTENSEN J, RUEFLI A, GREENGARD P, LORING J: Biochem. Biophys. Res. Commun. (1993) 197:639-645. First demonstration of significant human PAPP expression in trans-genic animals.
- CHOI T, HOLLENBACH P, PEARSON B, UEDA R, WEDDELL G, KURAHARA C, WOODHOUSE C, KAY R, LORING J: Nat. Genet. (1993) 4: 117–123.
References to Patent Literature
- ISIS PHARMACEUTICALS INC, W09313114.
- THE GENERAL HOSPITAL CORPORATION & MIT, EP–586790.
- SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCI-ATES INC, W09309233.
- ROCKEFELLER UNIVERSITY, W09311762.
- ROCKEFELLER UNIVERSITY, US5242932.
- MIT, W09409370.
- AMERICAN CYANAMID COMPANY, EP–584452A1.
- ATHENA NEUROSCIENCES INC, W09316101.
- CHILDREN'S MEDICAL CENTER CORPORATION, W09401772.
- THE DUPONT MERCK PHARMACEUTICAL COMPANY, US5252463.
- ELI LILLY & COMPANY, EP–576152A1.
- A'rHENA NEUROSCIENCES INC, US5292652.
- MILES INC, EP–569777A2.
- ATHENA NEUROSCIENCES, W09321526.
- BRISTOL-MYERS SQUIBB COMPANY, W09405811.
- DEPARTMENT OF HEALTH AND HUMAN SERVICES, US5276059.
- DEPARTMENT OF HEALTH AND HUMAN SERVICES, W09401116.
- THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA, US5270165.
- HARVARD COLLEGE, W09315112.
- DUKE UNIVERSITY, W09409364.
- SCIOS NOVA INC, US5221607.
- THE UNIVERSITY OF MELBOURNE, W09310459.
- NV INNOGENETICS SA, EP–561087A1.
- DUKE UNIVERSITY, W09409155.
- DUPONT MERCK PHARMACEUTICAL COMPANY, US5234814.
- McLEAN HOSPITAL AND UNIVERSITY OF ROCHESTER, US5231000.
- BRIGHAM & WOMEN'S HOSPITAL, US5262332.
- SCHENK DB etal., W09410569.
- BECTON DICKINSON & CO, EP–557595A2.
- ATHENA NEUROSCIENCES INC, W09322676.
- MAX-PLANCK GESELLSCHAFT, EP–544942A1.
- UNIVERSITY OF CINCINNATI, W09402851.
- GENPHARM INTERNATIONAL INC, W09400569.
- TSI CORPORATION, W09314200.